New Data on Paxlovid Reported.
Am J Nurs
; 122(10): 59, 2022 10 01.
Article
in English
| MEDLINE | ID: covidwho-2037547
ABSTRACT
According to this study In a phase 2/phase 3 study of Paxlovid use in patients at standard risk for developing severe COVID-19, the primary end point of self-reported sustained alleviation of all symptoms for four consecutive days wasn't met.A nonsignificant risk reduction in hospitalizations and death was seen in a subgroup of patients who had at least one risk factor for severe COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Am J Nurs
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS